Skip to content
Home/Companies/HealthTech/Antidote

Antidote

HealthTech·UK·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Antidote?

Antidote is currently owned by LBO France through LBO France Venture (2016 vintage), since 2025.

Hand-verified · updated 2026-04-21

LBO France
Investor
LBO France
LBO France Venture · 2016 · VC

Key facts

HQUK
SectorHealthTech

More from LBO France Venture

Other portfolio companies in the same fund.

12.5
Active
TMTFrance· 2025
Mediaire
Active
HealthTechGermany· 2025
Siteflow
Siteflow
Active
TMTFrance· 2025
Colpad
Active
HealthcareFrance· 2024
Vestalis
Vestalis
Active
HealthcareFrance· 2023
Diabeloop
Diabeloop
Active
MedTechFrance· 2022

More PE-backed in HealthTech

Comparable healthtech deals from other GPs.

52North Health
52North Health
Active
Future Planet CapitalUK
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Advance Medical
Active
Summit PartnersUS
AdvancedMD
AdvancedMD
Active
Francisco PartnersUS
agilon health
agilon health
Active
CD&RUS
Akrivia Health
Akrivia Health
Active
Future Planet CapitalUK
Track Antidote

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Antidote?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Antidote.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue